Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1983 Feb;71(2):390–394. doi: 10.1172/JCI110781

Leupeptin Inhibits Adrenocorticotropic Hormone-induced Protein Breakdown in the Conscious Dog

Ben McCallister 1,2, William W Lacy 1,2, Phillip E Williams 1,2, Naji N Abumrad 1,2
PMCID: PMC436879  PMID: 6296201

Abstract

To elucidate the role of proteinase inhibitors in the regulation of protein breakdown in vivo, we measured the effect of leupeptin on the rate of appearance of leucine in the plasma compartment in overnight-fasted conscious dogs. Two groups of dogs were studied. The control group (I) received saline infusion, and the experimental group (II) was rendered hypercatabolic with daily administration of adrenocorticotropic hormone (ACTH) (500 U/d) for 4 d.

ACTH treatment increased plasma cortisol from 2±0.4 to 17±2 μg/dl (P < 0.005). It raised plasma leucine levels (μmol/liter) from 123±6 in I to 206±5 in II (P < 0.01) and its rate of appearance into the plasma compartment (micromoles per kilogram per minute) from 3.1±0.1 in I to 4.6±0.3 in II (P < 0.01). Whole blood alanine concentration (micromoles per liter) increased by 50% (from 387±31 to 577±53, P < 0.01) and whole blood glutamine concentration (micromoles per liter) increased from 653±51 to 917±93 (P < 0.01). Leupeptin infusion in the ACTH-treated group significantly decreased both the concentration of plasma leucine and its rate of appearance. Blood glutamine declined by 30% (P < 0.05) after leupeptin, but no effect on blood alanine was observed. Leupeptin had no effect on the saline control group.

These data indicate that leupeptin decreases the accelerated rate of protein breakdown induced by cortisol excess. The fact that it did not affect protein degradation in controls may indicate that control of protein breakdown in the postabsorptive state may differ from that during accelerated turnover. Thus, the antibiotic proteinase enzyme inhibitors may be potentially useful in treating conditions of inappropriate protein breakdown.

Full text

PDF
390

Images in this article

392Image
on p.392
393Image
on p.393

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abumrad N. N., Jefferson L. S., Rannels S. R., Williams P. E., Cherrington A. D., Lacy W. W. Role of insulin in the regulation of leucine kinetics in the conscious dog. J Clin Invest. 1982 Nov;70(5):1031–1041. doi: 10.1172/JCI110690. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Aguilar-Parada E., Eisentraut A. M., Unger R. H. Pancreatic glucagon secretion in normal and diabetic subjects. Am J Med Sci. 1969 Jun;257(6):415–419. doi: 10.1097/00000441-196906000-00008. [DOI] [PubMed] [Google Scholar]
  3. Clark A. F., Vignos P. J., Jr The role of proteases in experimental glucocorticoid myopathy. Muscle Nerve. 1981 May-Jun;4(3):219–222. doi: 10.1002/mus.880040308. [DOI] [PubMed] [Google Scholar]
  4. Goldberg A. L. Protein turnover in skeletal muscle. II. Effects of denervation and cortisone on protein catabolism in skeletal muscle. J Biol Chem. 1969 Jun 25;244(12):3223–3229. [PubMed] [Google Scholar]
  5. Goldberg A. L., St John A. C. Intracellular protein degradation in mammalian and bacterial cells: Part 2. Annu Rev Biochem. 1976;45:747–803. doi: 10.1146/annurev.bi.45.070176.003531. [DOI] [PubMed] [Google Scholar]
  6. Hershko A., Ciechanover A. Mechanisms of intracellular protein breakdown. Annu Rev Biochem. 1982;51:335–364. doi: 10.1146/annurev.bi.51.070182.002003. [DOI] [PubMed] [Google Scholar]
  7. Hopgood M. F., Clark M. G., Ballard F. J. Stimulation by glucocorticoids of protein degradation in hepatocyte monolayers. Biochem J. 1981 Apr 15;196(1):33–40. doi: 10.1042/bj1960033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Libby P., Goldberg A. L. Leupeptin, a protease inhibitor, decreases protein degradation in normal and diseased muscles. Science. 1978 Feb 3;199(4328):534–536. doi: 10.1126/science.622552. [DOI] [PubMed] [Google Scholar]
  9. Neff N. T., DeMartino G. N., Goldberg A. L. The effect of protease inhibitors and decreased temperature on the degradation of different classes of proteins in cultured hepatocytes. J Cell Physiol. 1979 Dec;101(3):439–457. doi: 10.1002/jcp.1041010311. [DOI] [PubMed] [Google Scholar]
  10. Rannels S. R., Jefferson L. S. Effects of glucocorticoids on muscle protein turnover in perfused rat hemicorpus. Am J Physiol. 1980 Jun;238(6):E564–E572. doi: 10.1152/ajpendo.1980.238.6.E564. [DOI] [PubMed] [Google Scholar]
  11. Ruder H. J., Guy R. L., Lipsett M. B. A radioimmunoassay for cortisol in plasma and urine. J Clin Endocrinol Metab. 1972 Aug;35(2):219–224. doi: 10.1210/jcem-35-2-219. [DOI] [PubMed] [Google Scholar]
  12. Shoji S., Pennington R. J. The effect of cortisone on protein breakdown and synthesis in rat skeletal muscle. Mol Cell Endocrinol. 1977 Jan;6(3):159–169. doi: 10.1016/0303-7207(77)90082-x. [DOI] [PubMed] [Google Scholar]
  13. Stracher A., McGowan E. B., Hedrych A., Shafiq S. A. In vivo effect of protease inhibitors in denervation atrophy. Exp Neurol. 1979 Dec;66(3):611–618. doi: 10.1016/0014-4886(79)90206-1. [DOI] [PubMed] [Google Scholar]
  14. Stracher A., McGowan E. B., Shafiq S. A. Muscular dystrophy: inhibition of degeneration in vivo with protease inhibitors. Science. 1978 Apr 7;200(4337):50–51. doi: 10.1126/science.635570. [DOI] [PubMed] [Google Scholar]
  15. Tomas F. M., Munro H. N., Young V. R. Effect of glucocorticoid administration on the rate of muscle protein breakdown in vivo in rats, as measured by urinary excretion of N tau-methylhistidine. Biochem J. 1979 Jan 15;178(1):139–146. doi: 10.1042/bj1780139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. WALL J. S., STEELE R., DE BODO R. C., ALTSZULER N. Effect of insulin on utilization and production of circulating glucose. Am J Physiol. 1957 Apr;189(1):43–50. doi: 10.1152/ajplegacy.1957.189.1.43. [DOI] [PubMed] [Google Scholar]
  17. Waxman L. Calcium-activated proteases in mammalian tissues. Methods Enzymol. 1981;80(Pt 100):664–680. doi: 10.1016/s0076-6879(81)80051-1. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES